Quantification analysis revealed that the microvascular density was significantly higher in the coinjection groups containing c-Kit+ ASCs than in the other injection groups (81.3 ± 3.1 vessels/mm2 versus 65.0 ± 10.0 vessels/mm2 in the c-Kit−ASCs + 4T1/EPCs group, p < 0.05; 37.3 ± 4.2 vessels/mm2 in the EPCs/4T1 group, p < 0.001; 23.7 ± 5.1 vessels/mm2 in the 4T1 group, p < 0.001, Figure 3(f)), suggesting that c-Kit+ ASCs may enhance EPC-mediated tumor angiogenesis of breast cancer. The gene discussed is KIT; the disease is breast cancer.